Clinical and laboratory Variables | Pre-ART | Post-ART | ||
---|---|---|---|---|
Unadjusted HR (95% CI) | Adjusted HR (95% CI) | Unadjusted HR (95% CI) | Adjusted HR (95% CI) | |
Sex | ||||
Female | 1 | 1 | ||
Male | 2.07 (0.98 to 4.35) | 1.31 (0.60 to 2.88) | ||
Type of HIV | ||||
HIV-2 | 1 | 1 | ||
HIV-1 | 3.61 (1.05 to 12.4) | 0.81 (0.31 to 2.13) | ||
Double infected | 2.53 (0.54 to 11.8) | 1.31 (0.38 to 4.49) | ||
Baseline CD4 (cells/μl) | ||||
≤200 | 18.3(6.12 to 54.7) | 1.71 (0.62 to 4.67) | ||
>200 | 1 | 1 | ||
≤350 | 12.6 (2.95 to 53.8) | 5.33 (1.15 to 24.8) | – | – |
>350 | 1 | 1 | 1 | 1 |
SuPAR (ng/ml) | ||||
First quartile (0.22–2.54) | 1 | 1 | 1 | 1 |
Second quartile (2.54–3.53) | 0.48 (0.04 to 5.62) | 0.45 (0.04 to 5.09) | – | 0.00 |
Third quartile (3.53–5.31) | 1.89 (0.32 to 11.1) | 1.24 (0.20 to 7.65) | 1.24 (0.29 to 5.29) | 1.29 (0.30 to 5.54) |
Fourth quartile (5.31–38.7) | 19.0 (4.38 to 82.7) | 10.7 (2.38 to 48.4) | 5.32 (1.52 to 18.7) | 5.09 (1.45 to 17.9) |
BMI (kg/m2) | ||||
≤18.5 | 2.30 (1.10 to 4.82) | 1.87 (0.88 to 3.98) | ||
>18.5 | 1 | 1 | ||
MUAC (mm) | ||||
First quartile (116–231) | 19.3 (4.26 to 87.6) | 5.32 (1.16 to 24.4) | ||
Second quartile (232–261) | 8.24 (1.76 to 38.6) | 3.85 (0.82 to 18.0) | ||
Third quartile (262–285) | 4.63 (0.88 to 24.5) | 1.53 (0.24 to 9.62) | ||
Fourth quartile (286–390) | 1 | 1 | ||
≤250 | 5.27 (2.34 to 11.9) | 2.36 (1.01 to 5.55) | ||
>250 | 1 | 1 |
The analysis includes 628 patients with available MUAC, BMI and suPAR. Of the 628 contributed 625 with pre-ART risk time.
ART, antiretroviral therapy; BMI, body mass index; CD4, CD4+ T-cell; MUAC, middle-up-arm circumference; suPAR, soluble urokinase-type plasminogen activator receptor.